Targeting fcγriib by antagonistic antibody bi-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma

HIGHLIGHTS

• who: Vivian Changying Jiang from the Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Holcombe Blvd, Houston, TX, USA have published the research: Targeting Fcu03b3RIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma, in the Journal: (JOURNAL)
• how: Next the authors investigated whether BI-1206 can sensitize MCL tumors to rituximab by leveraging a rituximab-resistant PDX model (PDX-B) which was derived from a patient post-subsequent failure to rituximab ibrutinib and CAR T-therapy. To further improve the BI . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.